15 research outputs found

    <i>In silico</i> analysis of the effect of CDH13 variants.

    No full text
    <p>The analysis was based on the protein sequence. SIFT scores below 0.05 were considered damaging. I-mutant-3.0 predicted the effects of the variants on protein stability by calculating the unfolding Gibbs free energy value of the mutant proteins minus that of the wild type protein (ΔΔG = ΔG mutant – ΔG wild type), given in kcal/mol. A negative change indicates decreased stability. The reliability index (RI) for a large decrease (ΔΔG<−0.5) ranged from 0–10. For the G113R* a reliability index for a neutral stability change was given. Ternary classification (SVM3) −0.5< = ΔΔG< = 0.5 corresponds to neutral stability, ΔΔG<−0.5 to large decrease of stability and ΔΔG >0.5 to a large increase of stability.</p

    Schematic description of the CDH13 proteins expressed in CHO and HEK293 cells.

    No full text
    <p>CDH13 was expressed with or without a C-terminal tGFP tag in HEK293 and CHO cells, respectively. The location of the identified variants is also shown (A). According to the general model of processing of GPI anchored proteins in the ER, a C-terminal transmembrane domain is cleaved off and is then replaced by a GPI anchor. The protein with the attached GPI anchor is then directed to the external side of the plasma membrane (B). Wild type and variant CDH13 proteins were expressed on the cell membrane in HEK293 and CHO cells. In HEK293 cells, the C-terminal GFP tag of the GFP-CDH13 fusion proteins was cleaved off as a result of GPI anchoring at the c- terminal of CDH13 and the fully processed protein was subsequently transferred to the cell membrane.</p

    Frequency of <i>CDH13</i> variant alleles identified in Norwegian adult patient and control groups.

    No full text
    <p>Seven <i>CDH13</i> variants were identified in the sequencing study, three of which were only detected in patients. All variants were genotyped in a larger sample. Two-tailed P-values for genotype frequencies were calculated by Fisher’s exact test in a 2×2 contingency table.</p

    Genetic and molecular findings.

    No full text
    <p>A: coverage analysis of whole-genome sequencing data in patient 3 shows a clear regional drop in sequencing depth (red line) corresponding to the 45,049 bp deletion in the 5’-UTR of the <i>SLC19A3</i> gene. The two arrows mark the position of the break-points. Coverage in the same region of a control is shown in the bottom lane for comparison. The blue diagram depicts the SLC19A3 gene in a 3’-5’ alignment. Vertical rectangulars show the proportional position of the exons. B: Western blot analysis in frontal cortex homogenate of patient 1 using two primary antibodies (left and right panel) shows an increase of SLC19A3 protein immunoreactivity in the patient (P) compared to two age and gender matched controls (C1, C2).</p

    Neuroimaging findings.

    No full text
    <p>A: axial T2 weighted MRI of patient 2 taken during an episode with seizures, increasing encephalopathy and exacerbation of the dystonia. Images show bilateral high T2-signal changes and swelling in the putamen and caudate head. In addition there are multiple cortical lesions preferentially occurring in the depths of sulci, which is typical of BBGD. B: axial T2 and coronal T2-FLAIR weighted MRI of patient 1 taken during an episodic exacerbation show a similar pattern with bilateral striatal and multiple cortical lesions. The signal abnormalities regressed completely on later scans (not shown). C (upper lane): FDG-PET scan of the brain of patient 1 taken ~5 years later shows multiple foci of decreased glucose metabolism that correlate to the localization of the transient cortical signal changes on MRI. The striatum shows minimal uptake consistent with severe neuronal loss. A normal scan is shown in the lower lane for comparison.</p

    Partial pedigrees of the nine MODY families investigated.

    No full text
    <p>Squares represent male family members, circles female, and diamonds sex unknown. Numbers inside diamonds show the number of siblings. Black and grey symbols represent persons with diabetes and impaired glucose tolerance, respectively. An arrow denotes the proband in each family and stars indicate those subjects for whom DNA was available. Data under the symbols represent from top to bottom: age at diabetes diagnosis, mutation carrier status (N = Normal allele, M = Mutation), BMI and treatment (INS =  Insulin, OHA = Oral Hypoglycemic Agents).</p